Brad Heller, PhD is the original founder and CEO of Achieve Clinics.

Before Achieve, Brad was a scientist at a cell therapy company called Eureka Therapeutics. He learned first-hand how incredible these medicines can be, but also how difficult they are to make and for patients to access. While at Eureka, Brad co-authored a paper showing that cell therapy can drive a durable complete response in a metastatic hepatocellular carcinoma patient; he also co-invented the next generation of this technology which is now in clinical trials. Before this, Brad worked at a stealth mode biotech founded by Frank McCormick (inventor of sorafenib), where he co-invented small molecule degraders of Raf (PROTACs).

Brad’s academic career began at Princeton University (BA, Molecular Biology), continued at NYU School of Medicine (PhD, Neuroscience) and concluded at the University of California, San Francisco (Postdoctoral work). He has published papers in Nature, The Journal of Cell Biology and Scientific Reports.